Tirzepatide vs Semaglutide: a pharmacology comparison
Tirzepatide and semaglutide are the two most studied incretin-based compounds in contemporary metabolic research, and they are frequently discussed as if they were variations on the same molecule. They are not. They differ in the number of receptors they engage, in the peptide backbone they are built on, and in the clinical programmes that generated their data. This guide sets out those differences from a research standpoint.
Receptor targets
Semaglutide is a mono-agonist: it binds the glucagon-like peptide-1 (GLP-1) receptor and nothing else. GLP-1 receptor activation slows gastric emptying, suppresses glucagon secretion, and engages hypothalamic satiety pathways.
Tirzepatide is a dual agonist. It binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, with notably higher affinity for GIP. GIP receptor activation potentiates glucose-dependent insulin secretion from pancreatic beta cells and is implicated in adipose tissue lipid handling and energy expenditure.
The practical consequence for research design is that tirzepatide cannot be treated as a more potent semaglutide. Adding a second receptor changes which pathways are engaged, not merely how strongly.
Molecular design
Semaglutide is a 31-amino-acid analogue of native human GLP-1, modified at position 8 to resist degradation by dipeptidyl peptidase-4 (DPP-4), with a C18 fatty di-acid chain attached via a spacer at position 26.
Tirzepatide is a 39-amino-acid peptide built on the native GIP sequence rather than the GLP-1 sequence, with modifications that confer cross-reactivity at the GLP-1 receptor, and a C20 fatty di-acid moiety.
In both cases the fatty di-acid enables reversible albumin binding, which is what extends circulation time from minutes to days. The difference in chain length (C18 versus C20) is one contributor to their differing half-lives.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptor targets | GLP-1 | GIP + GLP-1 |
| Peptide backbone | GLP-1 analogue | GIP analogue |
| Amino acids | 31 | 39 |
| Albumin-binding moiety | C18 fatty di-acid | C20 fatty di-acid |
| Approximate half-life | ~7 days | ~5 days |
| Originator | Novo Nordisk | Eli Lilly |
| Trial programmes | SUSTAIN, STEP | SURPASS, SURMOUNT |
Trial programmes
Semaglutide data comes principally from the SUSTAIN programme, which examined glycaemic endpoints, and the STEP programme, which examined body-composition endpoints.
Tirzepatide data comes from the SURPASS programme and the SURMOUNT programme, structured along broadly parallel lines.
SURPASS-2 is the study most often cited in comparisons, because it placed the two compounds head to head under a single protocol rather than relying on cross-trial inference. Cross-trial comparison between separate programmes is unreliable — populations, baselines and endpoints rarely align closely enough to support it.
What this means for handling
Both compounds are supplied here as prefilled injection pens rather than lyophilised vials, which removes reconstitution as a variable but makes cold-chain handling and expiry tracking more important.
Both are peptides and both degrade with heat, light and repeated freeze-thaw cycling. Neither should be assessed for identity or purity on the basis of appearance — that is what the batch certificate is for.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. This material is provided for laboratory reference and is not medical advice.